BMS-986523

DRUG2 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb

Conditions

Advanced Solid MalignanciesAdvanced Solid Tumor MalignanciesColorectal Cancer (CRC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

RecruitingNCT07223047

Bristol-Myers SquibbAdvanced Solid Malignancies, Colorectal Cancer (CRC), Non-small Cell Lung Cancer (NSCLC) +1

Start: 2025-11-25End: 2028-10-13Target: 252Updated: 2026-05-28

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies

Not yet recruitingCTIS2025-523547-35-00

Bristol-Myers Squibb Services Unlimited CompanyAdvanced Solid Tumor Malignancies

Target: 16Updated: 2026-04-09